Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Alx Oncology Holdings is a biotechnology business based in the US. Alx Oncology Holdings shares (ALXO) are listed on the NASDAQ and all prices are listed in US Dollars. Alx Oncology Holdings employs 44 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $8.10 |
|---|---|
| 52-week range | $5.82 - $81.19 |
| 50-day moving average | $10.16 |
| 200-day moving average | $28.77 |
| Wall St. target price | $43.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.32 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.1 from 2022-06-29
| 1 week (2022-06-23) | 8.72% |
|---|---|
| 1 month (2022-05-27) | 0.62% |
| 3 months (2022-03-26) | N/A |
| 6 months (2021-12-30) | -63.06% |
| 1 year (2021-06-30) | -85.19% |
|---|---|
| 2 years (2020-06-26) | N/A |
| 3 years (2019-06-26) | N/A |
| 5 years (2017-06-26) | N/A |
| Gross profit TTM | $107,000 |
|---|---|
| Return on assets TTM | -14.77% |
| Return on equity TTM | -24.62% |
| Profit margin | 0% |
| Book value | $8.45 |
| Market capitalisation | $303.1 million |
TTM: trailing 12 months
We're not expecting Alx Oncology Holdings to pay a dividend over the next 12 months.
ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.